Cargando…
Retinoic acid and arsenic trioxide in the treatment of acute promyelocytic leukemia: current perspectives
Acute promyelocytic leukemia (APL) is a distinct subtype of acute myeloid leukemia (AML) with a unique morphological appearance, associated coagulopathy and canonical balanced translocation of genetic material between chromosomes 15 and 17. APL was first described as a distinct subtype of AML in 195...
Autores principales: | McCulloch, Derek, Brown, Christina, Iland, Harry |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5359123/ https://www.ncbi.nlm.nih.gov/pubmed/28352191 http://dx.doi.org/10.2147/OTT.S100513 |
Ejemplares similares
-
Retinoic acid and arsenic trioxide in the treatment of acute promyelocytic leukemia: current perspectives [Corrigendum]
Publicado: (2017) -
Retinoic acid and arsenic trioxide sensitize acute promyelocytic leukemia cells to ER stress
por: Masciarelli, S, et al.
Publicado: (2018) -
Real world data with concurrent retinoic acid and arsenic trioxide for the treatment of acute promyelocytic leukemia
por: Kulkarni, Uday P., et al.
Publicado: (2022) -
Effect of additional cytogenetic abnormalities on survival in arsenic trioxide-treated acute promyelocytic leukemia
por: Epstein-Peterson, Zachary D., et al.
Publicado: (2022) -
Retinoic Acid and Arsenic for Treating Acute Promyelocytic Leukemia
por: Zhou, Guang-Biao, et al.
Publicado: (2005)